- CA$130.80m
- CA$170.26m
- $55.50m
Brief: HLS Therapeutics Says Findings Continue To Reinforce Scientific Data And Clinical Use Of Vascepa To Reduce Cardiovascular Risk
Brief: HLS Therapeutics Announces Q3 Fiscal 2023 Financial Results And Renewal Of Normal Course Issuer Bid
Brief: Hls Therapeutics Announces Updates To Its Credit Agreement
Brief: HLS Therapeutics Announces Updates To Its Board Of Directors
Brief: HLS Therapeutics Announces Agreement With Polar Asset Management Partners
Brief: Hls Therapeutics Announces Q1 Fiscal 2023 Financial Results
Brief: Hls Therapeutics Announces CEO Transition
Canada Research Roundup: Alimentation Couche-Tard, Empire Company, Premium Brands Holdings
Brief: Hls Therapeutics Announces Board Appointment
Brief: Hls Therapeutics Announces Q3 Fiscal 2022 Financial Results
Brief: Hls Therapeutics Announces Updates To Its Credit Agreement
Brief: HLS Therapeutics reports Q2 results
Brief: HLS Therapeutics - Effective August 1, Entered Product Listing Agreement With Saskatchewan Drug Plan, For Listing & Public Reimbursement Of Vascepa
Brief: HLS Says Vascepa Is Now Reimbursed By Ontario's Provincial Drug Plan
Brief: HLS Therapeutics Obtains Public Reimbursement For Vascepa In New Brunswick And With Other Public Payors
Founder Bill Wells To Retire
Brief: HLS Therapeutics Obtains Public Reimbursement For Vascepa In Quebec
Brief: HLS Therapeutics Announces Q1 Fiscal 2022 Financial Results
Brief: HLS Therapeutics Completes Negotiations With PCPS For Vascepa